Evidence map›Paper›PMID 36484334›Full record

ArticleThoracic cancer2023

Primary lung sebaceous carcinoma successfully treated with radiotherapy and pembrolizumab: A case report.

Yasumiko Jodai, Shohei Hamada, Mikiko Yamada, Yuiko Masuda, Moriyasu Anai, Takayuki Jodai, Yusuke Tomita, Sho Saeki, Hidenori Ichiyasu, Takuro Sakagami

Open access · goldAbstract readCase Reports
In one paragraph

Article in Thoracic cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yasumiko JodaiRespiratory Medicine, Kumamoto University, Kumamoto, Japan.
Shohei HamadaRespiratory Medicine, Kumamoto University, Kumamoto, Japan.ORCID https://orcid.org/0000-0002-5950-7821
Mikiko YamadaRespiratory Medicine, Kumamoto University, Kumamoto, Japan.
Yuiko MasudaRespiratory Medicine, Kumamoto University, Kumamoto, Japan.
Moriyasu AnaiRespiratory Medicine, Kumamoto University, Kumamoto, Japan.
Takayuki JodaiRespiratory Medicine, Kumamoto University, Kumamoto, Japan.
Yusuke TomitaRespiratory Medicine, Kumamoto University, Kumamoto, Japan.
Sho SaekiRespiratory Medicine, Kumamoto University, Kumamoto, Japan.
Hidenori IchiyasuRespiratory Medicine, Kumamoto University, Kumamoto, Japan.
Takuro SakagamiRespiratory Medicine, Kumamoto University, Kumamoto, Japan.
Kumamoto Health Science University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sebaceous carcinoma is a rare cutaneous malignant tumor, usually occurring on the eyelids, head, neck, and trunk. There have been few reports about sebaceous carcinoma with primary lung cancer, for which optimal therapy has not yet been established. A 70-year-old man presented with a mass in the left iliac bone and tumor of the lower left lung. The morphological characteristics of the iliac bone biopsy pathology and immunostaining results showed sebaceous gland differentiation. After systemic examination, we diagnosed a primary lung sebaceous carcinoma with intrapulmonary and bone metastases. PD-L1 was positive in 1%-24% of tumor cells, and microsatellites were stable. We detected protein kinase B (AKT1) mutations using the Oncomine Dx target test. Palliative radiotherapy (RT) of a total of 45 Gy was provided in 15 fractions to the left iliac region, which resulted in a 25% reduction in the tumor size. Subsequently, four courses of first-line pembrolizumab led to a 30% reduction in the total tumor count. RT and pembrolizumab may be treatment options for certain rare primary sebaceous carcinomas of the lungs. A synergistic effect from RT and subsequent administration of immune checkpoint inhibitors may have contributed to tumor reduction.

Indexed as

CarcinomaLung NeoplasmsSebaceous Gland NeoplasmsSkin NeoplasmsAgedAntibodies, Monoclonal, HumanizedHumansLungMaleAntibodies, Monoclonal, Humanizedpembrolizumabpembrolizumabprimary lung sebaceous carcinomaradiotherapy

Identifiers

PMID36484334
PMCPMC9870725
OpenAlexW4310940707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.